LevelsRx review

Publishing anything at all before an intake puts LevelsRx ahead of a real share of this category, and it publishes three monthly figures. The trouble is that none of them is attached to anything. Semaglutide and tirzepatide are both named somewhere on the site, but neither is tied to a specific plan, so a reader looking at the cheaper figure and the dearer one cannot tell whether the gap between them is the difference between the two drugs, between two dose tiers, or between two levels of service. Every figure is also a starting point, with nothing published about what it starts from — not a dose, not a plan length, not a first month. Put those together and the numbers stop being prices and become a range with no axis. For the question this site exists to answer, a floor with no dose behind it is the least useful shape published pricing can take: it tells you the cheapest thing might cost this much, without telling you what the cheapest thing is. No pharmacy is named and no state coverage is published either.

Vs median

$25/mo below the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

LevelsRx does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

LevelsRx publishes three monthly figures before any intake, which puts it ahead of the part of this category that publishes nothing. What it does not do is connect any of them to anything. Each price is a "starting at", so each is a floor of unstated depth. Semaglutide and tirzepatide are both named somewhere on the site, but neither is attached to a particular plan, so a reader looking at $150 and $240 cannot tell whether the gap is the difference between the two molecules, between two dose tiers, or between two service levels. No dose appears behind any figure. For the question this site exists to answer — what does it cost to hold a small dose — there is nothing here to work with beyond a floor, and a floor without a dose is the least useful shape a published price can take.

Every figure is a "starting at" with nothing published about what it starts from.

• No molecule is attached to any specific plan, so the price gap cannot be explained.
• No dose, no named pharmacy and no state coverage published.

LevelsRx is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• What the evidence actually shows
• The true annual cost of a plan
• What a flat price costs at a low dose